Bactericidal activity study of the newest anti-tuberculosis compound QP-42 completed

Evaluation of bactericidal activity (ability to cause the death of the microorganism) of the substance QP42 in vitro was determined in the automated system Bactec MGIT 960. The precipitate the bacterial cells from the tubes, where growth has been identified in the presence of the substance QP42, washed and inoculated into a test tube with fresh nutrient medium without drug for 42 days. The lack of growth in fresh nutrient medium shows the bactericidal action of the drug. The drug, which has bactericidal properties, is considered more promising, because leads to the elimination of the causative agent. The control compound is rifampicin. The results are shown in Table 1.

Table. 1. Test results on the bactericidal activity of the drug candidate QP42
Drug Dose (mg/ml) The presence of culture growth, incubation 42 days
QP42 3,70 yes
QP42 11,11 no
QP42 33,33 no
QP42 100 no
Rifampicin 0,41 yes
Rifampicin 1,23 no
Rifampicin 3,70 no
Rifampicin 11,11 no
Rifampicin 33,33 no
Rifampicin 100 no

In conclusion, the studies of bactericidal activity of the drug QP42 on this cultivation in the automated detection system Bactec MGIT 960 showed that it possesses bactericidal activity against M.tuberculosis H37Rv strain at concentrations of 11.11 mg / ml.

Related posts:

  1. Quantum tests a novel targeted anti-tuberculosis compound
  2. QP42 in-vitro efficacy summary (MDR, XDR strains, other drugs/drug candidates)

About Peter Fedichev, Quantum CTO

Peter Fedichev, Ph.D., Chief Scientific Officer, co-founder